26
|
Kodaira M, Yonemori K, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. 576P Wilms tumor gene (WT-1) expression in female patients with unfavorable subset of cancer of unknown primary site. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw603.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Oshiro Y, Shimoi T, Okuma H, Kawai A, Shimomura A, Noguchi E, Yunokawa M, Shimizu C, Yonemori K, Fujiwara Y, Tamura K. 518P Feasibility and outocome of adult patients with osteosarcoma of the jaws. A single institute experience-. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Noguchi E, Yonemori K, Shimoi T, Yunokawa M, Okuma H, Kawachi A, Kitano A, Nishikawa T, Shimomura A, Shimizu C, Takiguchi Y, Kawai A, Fujiwara Y, Tamura K. 154P Clinical trial designs for the approval of rare cancer drugs in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Shimoi T, Hamada A, Kitamura Y, Nishijo T, Shimomura A, Shimizu C, Yoshida M, Kinoshita T, Fujiwara Y, Tamura K. 33P Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00193-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
30
|
Inagaki C, Shimoi T, Okuma H, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 510P Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Nishikawa T, Yonemori K, Kitano A, Shimoi T, Noguchi E, Yunokawa M, Shimizu C, Fujiwara Y, Yoshida A, Kobayashi E, Nakatani F, Kawai A, Chuman H, Koyama T, Shimomura A, Kitano S, Shimizu T, Fujiwara Y, Yamamoto N, Tamura K. 511P Retrospective study of sarcoma in practical and developmental therapeutics in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Oshiro Y, Shimoi T, Okuma H, Kawai A, Shimomura A, Noguchi E, Yunokawa M, Shimizu C, Yonemori K, Fujiwara Y, Tamura K. 518P Feasibility and outocome of adult patients with osteosarcoma of the jaws. A single institute experience-. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00676-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
33
|
Tsushita N, Shimoi T, Okuma H, Kawachi A, Kitano A, Nishikawa T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 118P A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw577.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Ebata T, Yunokawa M, Bun S, Noguchi E, Shimomura A, Shimoi T, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K. 312P Elevated serum CA125 predicts recurrence in patients with completely resected ovarian clear cell carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw585.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Kodaira M, Yonemori K, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. The prognostic impact of the putative primary site of breast and ovarian cancers in an unfavorable subset of cancer of unknown primary site. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw393.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Matsumoto K, Tamura K, Yoshida H, Nishikawa T, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Hashiba H, Kiriyama T, Leahy T, Shepherd S, Fujiwara K. A phase 1 study of single agent veliparib in Japanese subjects with advanced solid tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Nishikawa T, Yonemori K, Okuma H, Kawachi A, Kitano A, Shimoi T, Shimomura A, Noguchi E, Yunokawa M, Yoshida H, Shimizu C, Fujiwara Y, Tamura K. Overxpression of HER2/neu in uterine carcinosarcoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
38
|
Tanabe Y, Shiraishi S, Nishizawa D, Hamada A, Hasegawa J, Ozaki Y, Tamura N, Shimomura A, Yunokawa M, Yonemori K, Takano T, Kawabata H, Ikeda K, Tamura K, Fujiwara Y, Shimizu C. Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Tamura K, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Fujisaki Y, Yver A, Doi T. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.07] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Abstract P3-14-10: Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-14-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Taselisib (GDC-0032) is an orally bioavailable, potent and selective phosphoinositide 3-kinase (PI3K) inhibitor. Preclinical data showed that taselisib had increased antitumor activity against PIK3CA (gene encoding the PI3Kα isoform) mutant tumors. This study aimed to investigate the safety, tolerability and pharmacokinetics (PK) of taselisib as monotherapy and in combination with fulvestrant in Japanese patients (pts).
Materials and methods:
A 3+3 design was used. In Phase Ia, pts with advanced solid tumors received taselisib tablet monotherapy (2, 4 or 6 mg once daily [QD]), and safety and PK were evaluated. In Phase Ib, pts with hormone receptor-positive locally advanced or metastatic breast cancer received taselisib (2 or 4 mg QD) in combination with fulvestrant (500 mg at a time), and safety and PK were evaluated. Maximal administered doses of 6 mg QD as a single agent and 4 mg QD in combination with fulvestrant were based upon prior clinical trial experience with taselisib (Juric D. et al. AACR 2013, Abstract LB-64; Juric D. et al. SABCS 2013, Abstract PD1-3).
Results:
As of 15 Mar 2015, 9 pts (PIK3CA mutant: 2 pts) were enrolled in Phase Ia and 3 pts in Phase Ib. Phase Ia dose-escalation study has been completed and Phase Ib is ongoing.
In Phase Ia, no dose-limiting toxicity (DLT) was observed at any dose level tested (maximum administered dose of 6 mg QD). Common (≥3 pts) adverse reactions (ARs) were stomatitis (4 pts), rash (3 pts) and diarrhea (3 pts); the only Grade ≥3 AR was neutropenia (1 pt). Partial response was observed in 1 pt who received taselisib 4 mg and had a PIK3CA mutant breast tumor. Stable disease was observed in 4 pts. Cmax and AUC indicated a dose-proportional PK profile of taselisib within the dose range tested. Moreover, taselisib PK in Japanese pts was consistent with the PK reported from North American and European pts (Juric D. et al. AACR 2013, Abstract LB-64).
In Phase Ib, 3 pts received taselisib 2 mg in combination with fulvestrant and no DLT was observed. Preliminary ARs were similar to those with monotherapy and no Grade ≥3 AR was reported. Confirmation of tolerability of taselisib 4 mg in combination with fulvestrant is under evaluation.
Conclusion:
Taselisib monotherapy was well tolerated in Japanese pts up to a dose of 6 mg, which is the recommended dose in non-Japanese pts. Promising preliminary activity of monotherapy was observed in advanced solid tumors, especially in a pt with PIK3CA mutant tumor. The combination of taselisib 2 mg with fulvestrant is well tolerated. Investigation of tolerability of taselisib 4 mg in combination with fulvestrant is ongoing. Final results of this study will be presented here at the Symposium this year.
Citation Format: Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-10.
Collapse
|
41
|
Nishikawa T, Tanabe Y, Tsuda H, Yoshida M, Shimoi T, Shimomura A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 66P Predictive markers of clinical progressive disease during neoadjuvant chemotherapy in early triple negative breast cancers. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Kawachi A, Okochi-Takada E, Shimoi T, Shimomura A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Ushijima T, Tamura K. 98P BRCA1 methylation in triple-negative breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.47] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Kodaira M, Yonemori K, Yoshida A, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. 445 Clinical utility of chemotherapy based on the estimated primary organ in patients with cancer of unknown primary site. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30279-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Sasada S, Kodaira M, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 3433 Peripheral neuropathy caused by vincristine-containing chemotherapy for adult soft tissue sarcoma: A comparison between young and older adults. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31906-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Ling L, Bulik D, Duffner J, Shimizu C, Sarvaiya H, Kapoor B, Brown J, Markowitz L, Arevalo E, Schultes B, Capila I, Saldova R, Stockmann H, Albrecht S, McManus C, Rudd P, Kaudinya G, Manning A, Tremoulet A, Bosques C, Burns J. OP0197 High-Resolution, Integrated Molecular Profiling Reveals Persistent Inflammation in Kawasaki Disease Patients with Coronary Artery Aneurysms. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Yasuno H, Maeda M, Sato M, Nishimura A, Shimizu C, Miyamoto Y, Sotomatsu S. ORGAN CULTURE OF ADULT HUMAN SKIN. J Dermatol 2015; 7:37-47. [PMID: 15462074 DOI: 10.1111/j.1346-8138.1980.tb01941.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Proliferation and differentiation of the epidermis in organ culture of adult human skin by the sponge matrix method were studied histologically and autoradiographically, and the following results were obtained: 1) On the first day of culture, mitotic figures were already observable in the epidermis. The outgrowth of epidermal cells at the margins of the explants started. On the second day, there was transformation to a zone that will be referred to as the newly formed stratum corneum in the upper epidermis. 2) On the third and fourth days, the increased growth of epidermal cells caused thickening of the epidermis. Simultaneously, Malpighian cells progressively differentiated into a cornified layer. 3) On and after the fifth day, the basospinous cell layer was reduced in thickness in most of explants. On the ninth and tenth days, DNA synthesis in the basal layer was still obvious, although the epidermis showed a thickness of only one or two cells overlaid with a large number of horny layers. 4) In the culture medium supplemented with corticosteroid, the epidermal growth was slightly depressed with lessened formation of stratum corneum in the early stages of culture as compared with the explants cultured in the basic medium. The reduction of the basospinous layer was scarcely notable after the fifth day. Even after 10-11 days, epidermal cells were well preserved and their stratified squamous architecture was less disorganized. It seemed that corticosteroid could prolong the survival of adult human skin in vitro. These findings indicate that this culture technique could be used as a model for organ culture of adult human skin.
Collapse
|
47
|
Hironaka A, Tsuda H, Yoshida M, Shimizu C, Tamura K, Fujiwara Y, Hojo T, Kinoshita T, Maeshima A, Hiraoka N. P019 Histopathological features of operable breast cancer detected in women younger than 35 years. Breast 2015. [DOI: 10.1016/s0960-9776(15)70069-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
48
|
Tanabe Y, Tsuda H, Yoshida M, Kinoshita T, Kodaira M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. P025 Immunological factors to predict disease progression during neoadjuvant chemotherapy. Breast 2015. [DOI: 10.1016/s0960-9776(15)70075-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
49
|
Bando H, Ohno S, Kato T, Tamura N, Asada Y, Watanabe C, Tsugawa K, Suzuki N, Shimizu C. PO33 Clinical practice guideline for preservation of fertility in breast cancer patients in Japan. Breast 2014. [DOI: 10.1016/s0960-9776(14)70043-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
50
|
Tanaka R, Yonemori K, Hirakawa A, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk Factors for Developing Skeletal-Related Events Associated with Metastatic Breast Cancer Patients Receiving Bone-Modifying Agents. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|